Skip to main content

John Boyce

In 2013, John was named one of the top 15 Technology Luminaries in Massachusetts by the Boston Business Journal and Mass High Technology.

John is both a genomics and proteomics serial entrepreneur with seven successful exits and a venture capitalist focusing on therapeutics, tools, and diagnostics, specializing in building and positioning companies for either acquisition or an IPO. He has formed two successful venture capital firms – Tiger Gene, seeded by Tiger Management, and 28 Capital, a rebrand and expansion of Tiger Gene.

He has successfully raised over $800MM in funding and amassed >$1.8bn through exits. Before co-founding TigerGene Capital and John’s last exit as a serial entrepreneur, John was President and CEO of Exosome Diagnostics, which he led to a successful $575MM acquisition by Bio-Techne. John is also a Fellow at Harvard University, where he teaches ‘Entrepreneurship and Innovation.’